EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document C:2004:172:FULL

Official Journal of the European Union, C 172, 02 July 2004


Display all documents published in this Official Journal
 

ISSN 1725-2423

Official Journal

of the European Union

C 172

European flag  

English edition

Information and Notices

Volume 47
2 July 2004


Notice No

Contents

page

 

I   Information

 

Commission

2004/C 172/1

Euro exchange rates

1

2004/C 172/2

Notice of initiation of a partial interim review of the anti-dumping measures applicable to imports of ammonium nitrate originating in Russia and Ukraine

2

2004/C 172/3

Summary of Community decisions on marketing authorization in respect of medicinal products from 15/04/2004 to 15/05/2004 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

4

EN

 


I Information

Commission

2.7.2004   

EN

Official Journal of the European Union

C 172/1


Euro exchange rates (1)

1 July 2004

(2004/C 172/01)

1 euro=

 

Currency

Exchange rate

USD

US dollar

1,2168

JPY

Japanese yen

131,64

DKK

Danish krone

7,4335

GBP

Pound sterling

0,6701

SEK

Swedish krona

9,1615

CHF

Swiss franc

1,5232

ISK

Iceland króna

88,43

NOK

Norwegian krone

8,441

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5815

CZK

Czech koruna

31,875

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

251,35

LTL

Lithuanian litas

3,4529

LVL

Latvian lats

0,6563

MTL

Maltese lira

0,4262

PLN

Polish zloty

4,5005

ROL

Romanian leu

40 629

SIT

Slovenian tolar

239,85

SKK

Slovak koruna

39,845

TRL

Turkish lira

1 791 400

AUD

Australian dollar

1,7283

CAD

Canadian dollar

1,6172

HKD

Hong Kong dollar

9,4907

NZD

New Zealand dollar

1,9013

SGD

Singapore dollar

2,0875

KRW

South Korean won

1 402,54

ZAR

South African rand

7,5203


(1)  

Source: reference exchange rate published by the ECB.


2.7.2004   

EN

Official Journal of the European Union

C 172/2


NOTICE OF INITIATION

of a partial interim review of the anti-dumping measures applicable to imports of ammonium nitrate originating in Russia and Ukraine

(2004/C 172/02)

The Commission has received a request for a partial interim review pursuant to Article 11(3) of Council Regulation (EC) No 384/96 (1) (‘the basic Regulation’).

1.   Request for review

The request was lodged by the European Fertilizer Manufacturers Association (‘the applicant’).

2.   Product

The product under review is ammonium nitrate other than in aqueous solution and mixtures of ammonium nitrate with calcium carbonate or other inorganic non-fertilising substances, with a nitrogen content exceeding 28 % by weight, originating in Russia and Ukraine ('the product concerned'), normally classifiable within CN codes 3102 30 90 and 3102 40 90. These CN codes are given only for information.

3.   Existing measures

The measures currently in force are a definitive anti-dumping duty imposed by Council Regulation (EC) 132/2001 (2) on imports of ammonium nitrate originating, inter alia, in Ukraine and by Council Regulation (EC) No 658/2002 (3) on imports of ammonium nitrate originating in Russia.

4.   Grounds for the review

The applicant has provided information that the scope of the existing measure is no longer sufficient to counteract the dumping which is causing injury.

The applicant alleges that new product types have appeared on the market which should be included in the scope of the measures on the grounds that they share the same basic physical and chemical characteristics and end uses as the product covered by the measures. Both the product concerned and the new product types should therefore be considered as a single product.

5.   Procedure for the determination of dumping

Having determined, after consulting the Advisory Committee, that sufficient evidence exists to justify the initiation of a partial interim review, the Commission hereby initiates a review in accordance with Article 11(3) of the basic Regulation, limited in scope to the definition of the product concerned.

The investigation will assess the need for the amendment of the scope of the existing measure.

(a)   Questionnaires

In order to obtain the information it deems necessary for its investigation, the Commission will send questionnaires to the applicant, to the importers, to the users, to exporting producers in Russia and Ukraine, to the exporters and to the Russian and Ukrainian authorities. This information and supporting evidence should reach the Commission within the time limit set in point 6(a) of this notice.

(b)   Collection of information and holding of hearings

All interested parties are hereby invited to make their views known, submit information other than questionnaire replies and to provide supporting evidence. This information and supporting evidence must reach the Commission within the time limit set in paragraph 6(a) of this notice.

Furthermore, the Commission may hear interested parties, provided that they make a request showing that there are particular reasons why they should be heard. This request must be made within the time limit set in paragraph 6(b) of this notice.

6.   Time limits

(a)   For parties to make themselves known, to submit questionnaire replies and any other information

All interested parties, if their representations are to be taken into account during the investigation, must make themselves known by contacting the Commission, present their views and submit questionnaire replies or any other information within 40 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified. Attention is drawn to the fact that the exercise of most procedural rights set out in the basic Regulation depends on the party's making itself known within the aforementioned period.

(b)   Hearings

All interested parties may also apply to be heard by the Commission within the same 40-day time limit.

7.   Written submissions, questionnaire replies and correspondence

All submissions and requests made by interested parties must be made in writing (not in electronic format, unless otherwise specified and must indicate the name, address, e-mail address, telephone and fax, and/or telex numbers of the interested party). All written submissions, including the information requested in this notice, questionnaire replies and correspondence provided by interested parties on a confidential basis shall be labelled as ‘Limited’ (4) and, in accordance with Article 19(2) of the basic Regulation, shall be accompanied by a non-confidential version, which will be labelled ‘for inspection by interested parties’.

Commission address for correspondence:

European Commission

Directorate General for Trade

Directorate B

Office: J-79 5/16

B-1049 Brussels

Fax (32 2) 295 65 05

Telex COMEU B 21877.

8.   Non-co-operation

In cases in which any interested party refuses access to or otherwise does not provide the necessary information within the time limits, or significantly impedes the investigation, findings, affirmative or negative, may be made in accordance with Article 18 of the basic Regulation, on the basis of the facts available.

Where it is found that any interested party has supplied false or misleading information, the information shall be disregarded and use may be made, in accordance with Article 18 of the basic Regulation, of the facts available. If an interested party does not co-operate, or co-operates only partially, and use of the best facts available is made, the result may be less favourable to the party than if it had co-operated.


(1)  OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Regulation (EC) No 461/2004 (OJ L 77, 13.3.2004, p. 12).

(2)  OJ L 23, 25.1.2001, p. 1.

(3)  OJ L 102, 18.4.2002, p. 1.

(4)  This means that the document is for internal use only. It is protected pursuant to Article 4 of Regulation (EC) No 1049/2001 of the European Parliament and of the Council (OJ L 145, 31.5.2001, p. 43). It is a confidential document pursuant to Article 19 of Council Regulation (EC) No 384/96 (OJ L 56, 6.3.1996, p. 1) and Article 6 of the WTO Agreement on Implementation of Article VI of the Gatt 1994 (Anti-dumping Agreement).


2.7.2004   

EN

Official Journal of the European Union

C 172/4


Summary of Community decisions on marketing authorization in respect of medicinal products from 15/04/2004 to 15/05/2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 (1))

(2004/C 172/03)

Issuing of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

26.04.2004

Velcade

Millenium Pharmaceuticals Ltd

Building 3 Chiswick Park

566 Chiswick High Road

Chiswick

London W4 5YA

United Kingdom

EU/1/04/274/001

28.04.2004

28.04.2004

Lysodren

Laboratoire HRA Pharma

19, rue Frédérick Lemaitre

F-75020 Paris

EU/1/04/273/001

30.04.2004

28.04.2004

Dukoral

SBL Vaccin AB

S-105 21 Stockholm

EU/1/03/263/001-003

03.05.2004

Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

22.04.2004

Onsenal

Pharmacia-Pfizer EEIG

Hillbottom Road

High Wycombe

Bucks HP12 4PX

United Kingdom

EU/1/03/259/001-006

04.05.2004

22.04.2004

Kudeq

Pfizer Limited Sandwich

Kent CT13 9NJ

United Kingdom

EU/1/02/244/001-024

27.04.2004

22.04.2004

Bextra

Pharmacia-Pfizer EEIG

Hillbottom Road

High Wycombe

Bucks HP12 4PX

United Kingdom

EU/1/02/239/001-024

04.05.2004

22.04.2004

Dynastat

Pharmacia Europe EEIG

Hillbottom Road

High Wycombe

Buckinghamshire HP12 4PX

United Kingdom

EU/1/02/209/001-008

04.05.2004

22.04.2004

Rayzon

Pharmacia Europe EEIG

Hillbottom Road

High Wycombe

Buckinghamshire HP12 4PX

United Kingdom

EU/1/02/210/001-008

04.05.2004

28.04.2004

Zerit

Bristol-Myers Squibb Pharma EEIG

141-149 Staines Road

Hounslow TW3 3JA

United Kingdom

EU/1/96/009/001-017

30.04.2004

28.04.2004

Viracept

Roche Registration Limited

40 Broadwater Road

Welwyn Garden City

Hertfordshire AL7 3AY

United Kingdom

EU/1/97/054/006

30.04.2004

29.04.2004

Stocrin

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/99/111/001-009

07.05.2004

29.04.2004

Sustiva

Bristol-Myers Squibb Pharma EEIG

141-149 Staines Road

Hounslow TW3 3JA

United Kingdom

EU/1/99/110/001-009

04.05.2004

07.05.2004

Ferriprox

Apotex Europe Ltd

Rowan House

41 London Street

Reading

Berkshire RG1 4PS

United Kingdom

EU/1/99/108/001

11.05.2004

10.05.2004

Enbrel

Wyeth Europa Limited

Huntercombe Lane

South Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/99/126/001-003

12.05.2004

11.05.2004

Cancidas

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/01/196/001-003

13.05.2004

13.05.2004

Cancidas

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/01/196/001-003

17.05.2004

Issuing of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

07.05.2004

Equilis StrepE

Intervet International BV

Wim de Körverstraat, 35

5831 AN Boxmeer

Nederland

EU/2/04/043/001

11.05.2004

Modification of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

28.04.2004

SevoFlo

Abbott laboratories Ltd

Queenborough

Kent ME11 5EL

United Kingdom

EU/2/02/035/001-006

30.04.2004

28.04.2004

Locatim

Biokema Anstalt

Aeulestrasse 38

9490 Vaduz

Fürstentum Liechtenstein

EU/2/99/011/001

29.04.2004

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal products

7, Westferry Circus, Canary Wharf

LONDON E14 4HB

United Kingdom


(1)  OJ L 214 du 24 August 1993, page 1.


Top